Search Results for “diabetes” – Page 39 – media

Too much insulin can be as dangerous as too little

Just over a century has passed since the discovery of insulin, a time period during which the therapeutic powers of the hormone have broadened and refined. Insulin is an essential treatment for type 1 diabetes and often for type 2 diabetes, as well. Roughly 8.4 million Americans use insulin, according to the American Diabetes Association. One hundred years of research have greatly advanced medical and biochemical understanding of how insulin works and what happens when it is lacking, but the reverse, how potentially fatal insulin hyper-responsiveness is prevented, has remained a persistent mystery. In a new study, published in the April 20, 2023 online edition of Cell Metabolism, a team of scientists at the University of California San Diego School of Medicine, with colleagues elsewhere, describe a key player in the defense mechanism that safeguards us against excessive insulin in the body. “Although insulin is one of the most essential hormones, ...
- Source: drugdu
- 122
- April 25, 2023
In heavyweight obesity fight, Eli Lilly launches Mounjaro head-to-head trial against Novo Nordisk’s Wegovy

The stakes are getting even higher for the fight between Eli Lilly and Novo Nordisk for supremacy in the multibillion-dollar obesity market. Lilly on Friday quietly registered a new phase 3b trial on clinicaltrials.gov. The study, coded SURMOUNT-5, will pit Lilly’s Mounjaro against Novo’s Wegovy in patients with obesity or overweight with weight-related health conditions. The trial aims to enroll 700 participants from 61 sites in the U.S., Canada, South America and several European countries, according to the post. The study is currently expected to officially start next Friday and last for about 78 weeks, with an estimated primary completion date in February 2025. On the study’s primary endpoint, investigators will compare the percentage weight changes between the two drugs by week 72 from baseline. However, it’s not immediately clear whether Lilly is designing SURMOUNT-5 as a superiority study to show Mounjaro is better than Wegovy or just to show ...
- Source: drugdu
- 135
- April 25, 2023
Withdrawal of financial incentives for NHS GPs in Scotland linked to reductions in quality of care

Ending performance-related payments for NHS GPs in Scotland was associated with a decline in the quality of some aspects of care compared with England where financial incentives have continued, finds a study published by The BMJ today. The researchers say further research is needed to better understand the full impact of withdrawal and the accompanying refocusing of quality improvement resources. The NHS Quality and Outcomes Framework (QOF) pay-for-performance scheme began in 2004. It was designed to remunerate general practices for providing good quality care across a range of key areas such as cancer, diabetes, heart disease, mental health, and obesity. In 2016, Scotland abolished the QOF to reduce the bureaucratic burden on GPs and to free-up their time for patients, but continued collecting performance data for some QOF indicators for the next three years. Researchers were therefore able to use this data to evaluate the impact of ...
- Source: drugdu
- 132
- April 24, 2023
High fitness levels may reduce the risk of cardiovascular death

High fitness levels may reduce the risk of death from cardiovascular disease in men with high blood pressure, according to a 29-year study published today in the European Journal of Preventive Cardiology, a journal of the ESC. Nearly 1.3 billion adults aged 30 to 79 years worldwide have high blood pressure (hypertension). Hypertension is a major risk factor for heart attack and stroke and a leading cause of premature death globally. Previous studies have shown that high cardiorespiratory fitness is linked with greater longevity. This study examined the interplay between blood pressure, fitness and risk of death from cardiovascular disease. The study included 2,280 men aged 42 to 61 years living in eastern Finland and enrolled in the Kuopio Ischaemic Heart Disease Risk Factor Study. Baseline measurements were conducted between 1984 and 1989. These included blood pressure and cardiorespiratory fitness, which was assessed as maximal oxygen uptake while riding ...
- Source: drugdu
- 134
- April 24, 2023
Study reveals the risk factors associated with developing long Covid

Journal reference: Tsampasian, V., et al. (2023) Risk Factors Associated With Post−COVID-19 Condition. JAMA Internal Medicine. doi.org/10.1001/jamainternmed.2023.0750. Being vaccinated against Covid halves people’s risk of developing long Covid, according to new research from the University of East Anglia. Long Covid still affects some two million people in the UK, and new research published today reveals the risk factors associated with developing the condition. Overweight people, women, smokers and those over the age of 40 are also more likely to suffer from long Covid according to the study – which includes more than 860,000 patients and is thought to be the largest of its kind. The study also finds that co-morbidities such as asthma, COPD, Type 2 Diabetes, coronary heart disease, immunosuppression, anxiety and depression are also associated with increased risk of long Covid. And patients who are hospitalized during their acute Covid infection are also ...
- Source: drugdu
- 131
- April 19, 2023
Higher intake of flavonols linked to lower risk of frailty onset in adults

In a recent study published in The American Journal of Clinical Nutrition, researchers assessed the impact of consuming dietary flavanols on the likelihood of developing frailty. Frailty affects 10% to 15% of older persons and is causally associated with various age-related physiological changes. The need for research in the prevention and treatment of frailty is highlighted by the absence of effective therapies for frailty. Identifying risk factors associated with frailty is crucial for creating interventions that can delay, undo, or prevent its onset. A meta-analysis of several studies found that following a healthy dietary pattern may reduce the risk of frailty onset by 50% to 70%. Flavonoids have the potential to reduce inflammation and frailty development by mitigating the accumulation of oxidative stress and targeting the reduction of age-related senescent cells. About the study In the present study, researchers investigated the relationship between dietary flavonoids, including their subclasses ...
- Source: drugdu
- 111
- April 19, 2023
Mediterranean diet may lower heart disease risk in women by nearly 25%, study finds

Closely following a Mediterranean diet may cut a woman’s risk of heart disease and death by nearly 25%, according to a new analysis of 16 studies. “This study adds to what is already known about the cardiovascular benefits of a Mediterranean diet but further reiterates that it can be equally as beneficial in women as it is known to be in men,” said lead author Sarah Zaman, associate professor at the Westmead Applied Research Centre at the University of Sydney, in an email. Heart disease is the number one killer of women and men worldwide, according to the World Health Organization. Coronary artery disease kills more than twice as many women as breast cancer in the United Kingdom, while in 2020, one in five deaths among women in the United States was because of heart disease. Yet few studies on the heart have looked specifically at women, ...
- Source: drugdu
- 109
- April 13, 2023
WHO considers adding obesity drugs on its ‘essential medicines’ list

Drugs that combat obesity are under consideration for the first time for the World Health Organization’s “essential medicines list,” used to guide government purchasing decisions in low- and middle-income countries, the U.N. agency told Reuters. A panel of advisers to the WHO will review new requests for drugs to be included next month, with an updated essential medicines list due in September. The request to consider obesity drugs was submitted by three doctors and a researcher in the United States. It covers the active ingredient liraglutide in Novo Nordisk’s obesity drug Saxenda, which will come off patent soon, allowing for cheaper generic versions. The panel could reject the request or wait for more evidence. A decision by the WHO to include Saxenda and eventual generics on the list for adults would mark a new approach to global obesity by the health agency. It could also pave the way for a newer, more ...
- Source: drugdu
- 129
- April 6, 2023
Vaccination, Paxlovid decrease risk of long Covid, studies show

People who are vaccinated or who take Paxlovid during a Covid-19 infection have a lower risk of developing long Covid, new research shows. The US Centers for Disease Control and Prevention defines long Covid as new, returning or ongoing health issues more than four weeks after an initial infection. According to the CDC, 1 in 5 Covid-19 survivors ages 18 to 64 and 1 in 4 survivors 65 or older have an ongoing health issue that might be attributable to Covid-19 infection。 A study published Thursday in JAMA Internal Medicine analyzed data from 41 studies, including more 860,000 people around the world. Of the four studies with vaccination information of nearly 250,000 people, those who had been vaccinated against Covid-19 had almost half the risk of long Covid than people who weren’t vaccinated. “These findings are important because they enable us to better understand who may develop ...
- Source: drugdu
- 130
- March 30, 2023
Novo Nordisk and Dewpoint partner on insulin resistance drug candidates

Insulin resistance is becoming more prevalent, affecting 15.5% to 46.5% of the world’s population Novo Nordisk and Dewpoint Therapeutics have entered into a research and development partnership aimed at identifying drug candidates to treat insulin resistance and diabetic complications. A key driver of type 2 diabetes and metabolic syndrome, insulin resistance occurs when the body has an impaired response to insulin, resulting in elevated levels of glucose in the blood. The condition is rising in prevalence globally, affecting 15.5% to 46.5% of the world’s population. The collaboration will see the partners use Dewpoint’s discovery and AI technology platform to identify modulators of biomolecular condensates – membraneless organelles comprising proteins and RNA – that may be involved in insulin resistance and insulin sensitivity. The dysregulation of these condensates has been observed in many diseases, including diabetes, which is why Dewpoint believes that using its platform to develop ...
- Source: drugdu
- 135
- March 24, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.